top of page
  • EVI

International partnership to advance the development of a new vaccine against Shigella and ETEC

Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials in Europe and Bangladesh.

Under coordination by EVI, the SHIGETECVAX consortium, made up of partners including EVI, EveliQure, icddr,b, University of Gothenburg, and PATH, will be advancing a radically new approach for a vaccine against Shigella and ETEC, developed by EveliQure Biotechnologies.

Dr. Hilde Depraetere, Acting Executive Director of EVI, points out that “the strategy chosen by EveliQure in the design of the vaccine indeed explores the challenge of developing vaccines against Shigella and ETEC from a new angle. In combination with the new formulation of the vaccine that we plan to develop in the project, overall this represents a promising approach for developing an affordable vaccine for these two diseases”.

Dr. Depraetere adds that EVI plans to strengthen the organisation´s involvement in field of diarrheal diseases in the future

To read the full news release, see press release.

190910_SHIGETECVAX Launch_Press Release
Download • 162KB

bottom of page